Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
national blog main
alnylam pharmaceuticals
amgen
biotech ipos
fda
national top stories
new york blog main
new york top stories
novartis
san diego blog main
san diego top stories
the medicines company
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alirocumab
alopecia areata
amarin
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
axitinib
bellus health
bolt biotherapeutics
boston
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
cancer
cell therapy
cidara therapeutics
What
brings
3
×
drug
3
×
company
medicines
new
acquire
advantages
agreed
bar
billion
bio
cash
cholesterol
compound
deal
developing
disorders
dyne
dyne’s
expect
fda
gamble
genetic
ipo
market
medco
medco’s
million
mover
muscle
muscular
novartis
patients
payers
physicians
plan
poised
preclinical
pricing
raised
Language
unset
Current search:
brings
×
drug
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
